Glioblastoma in elderly patients: safety and efficacy of adjuvant radiotherapy with concomitant temozolomide. 2010

F Fiorica, and M Berretta, and C Colosimo, and A Stefanelli, and S Ursino, and E Zanet, and T Palmucci, and D Maugeri, and M Malaguarnera, and S Palmucci, and M Grasso, and U Tirelli, and F Cartei
Division of Radiotherapy, Arcispedale S'Anna Universitary Hospital, Ferrara, Italy. francesco.fiorica@unife.it

The aim of this study was to evaluate the impact of radiotherapy plus concomitant and adjuvant temozolomide (TMZ), in terms of feasibility and activity, in elderly patients with glioblastoma. From January 2002 to December 2007, 42 consecutive patients with glioblastoma (27 men and 15 women) aged 65 years or more (median age 71.3 years), received radiotherapy plus concomitant and adjuvant TMZ. Nineteen patients (45.2%) had a Karnofsky index >or=80. Thirty-six patients (85.8%) underwent complete or subtotal resection, while 6 patients (14.2%) were only biopsied. All patients received adjuvant radiotherapy within 4 weeks from surgery. Twenty-two patients (54.8%) underwent adjuvant TMZ. Early discontinuation of concomitant TMZ program due to toxicity was observed in 8 patients. Considered variables were: age, Karnofsky index, surgery versus no surgery, radiation dose, and chemotherapy. At a median follow-up of 10.2 months, the 6- and 12-month overall survival rates were 81.9% and 27.8%, respectively. There was a significantly better survival for patients with a performance status according to Karnofsky >80 (p<0.0001). Actuarial progression-free survival at 6- and 12-month was 46.4% and 9.8%, respectively. Globally, the treatment was well tolerated with no treatment-related toxicity in 69% of patients. In conclusion, in elderly patients, the adjuvant chemo-radiotherapy was well tolerated with an acceptable rate of toxicity, and patients with a good performance status had a significantly better survival. However, further prospective trials are needed to confirm these results.

UI MeSH Term Description Entries
D008279 Magnetic Resonance Imaging Non-invasive method of demonstrating internal anatomy based on the principle that atomic nuclei in a strong magnetic field absorb pulses of radiofrequency energy and emit them as radiowaves which can be reconstructed into computerized images. The concept includes proton spin tomographic techniques. Chemical Shift Imaging,MR Tomography,MRI Scans,MRI, Functional,Magnetic Resonance Image,Magnetic Resonance Imaging, Functional,Magnetization Transfer Contrast Imaging,NMR Imaging,NMR Tomography,Tomography, NMR,Tomography, Proton Spin,fMRI,Functional Magnetic Resonance Imaging,Imaging, Chemical Shift,Proton Spin Tomography,Spin Echo Imaging,Steady-State Free Precession MRI,Tomography, MR,Zeugmatography,Chemical Shift Imagings,Echo Imaging, Spin,Echo Imagings, Spin,Functional MRI,Functional MRIs,Image, Magnetic Resonance,Imaging, Magnetic Resonance,Imaging, NMR,Imaging, Spin Echo,Imagings, Chemical Shift,Imagings, Spin Echo,MRI Scan,MRIs, Functional,Magnetic Resonance Images,Resonance Image, Magnetic,Scan, MRI,Scans, MRI,Shift Imaging, Chemical,Shift Imagings, Chemical,Spin Echo Imagings,Steady State Free Precession MRI
D008297 Male Males
D001932 Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain. Brain Cancer,Brain Metastases,Brain Tumors,Cancer of Brain,Malignant Primary Brain Tumors,Neoplasms, Intracranial,Benign Neoplasms, Brain,Brain Neoplasm, Primary,Brain Neoplasms, Benign,Brain Neoplasms, Malignant,Brain Neoplasms, Malignant, Primary,Brain Neoplasms, Primary Malignant,Brain Tumor, Primary,Brain Tumor, Recurrent,Cancer of the Brain,Intracranial Neoplasms,Malignant Neoplasms, Brain,Malignant Primary Brain Neoplasms,Neoplasms, Brain,Neoplasms, Brain, Benign,Neoplasms, Brain, Malignant,Neoplasms, Brain, Primary,Primary Brain Neoplasms,Primary Malignant Brain Neoplasms,Primary Malignant Brain Tumors,Benign Brain Neoplasm,Benign Brain Neoplasms,Benign Neoplasm, Brain,Brain Benign Neoplasm,Brain Benign Neoplasms,Brain Cancers,Brain Malignant Neoplasm,Brain Malignant Neoplasms,Brain Metastase,Brain Neoplasm,Brain Neoplasm, Benign,Brain Neoplasm, Malignant,Brain Neoplasms, Primary,Brain Tumor,Brain Tumors, Recurrent,Cancer, Brain,Intracranial Neoplasm,Malignant Brain Neoplasm,Malignant Brain Neoplasms,Malignant Neoplasm, Brain,Neoplasm, Brain,Neoplasm, Intracranial,Primary Brain Neoplasm,Primary Brain Tumor,Primary Brain Tumors,Recurrent Brain Tumor,Recurrent Brain Tumors,Tumor, Brain
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D003606 Dacarbazine An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564) DTIC,5-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide,Biocarbazine,DIC,DTIC-Dome,Decarbazine,Deticene,Dimethyl Imidazole Carboxamide,Dimethyl Triazeno Imidazole Carboxamide,ICDT,NSC-45388,Carboxamide, Dimethyl Imidazole,DTIC Dome,DTICDome,Imidazole Carboxamide, Dimethyl,NSC 45388,NSC45388
D005260 Female Females
D005909 Glioblastoma A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures. Astrocytoma, Grade IV,Giant Cell Glioblastoma,Glioblastoma Multiforme,Astrocytomas, Grade IV,Giant Cell Glioblastomas,Glioblastoma, Giant Cell,Glioblastomas,Glioblastomas, Giant Cell,Grade IV Astrocytoma,Grade IV Astrocytomas
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077204 Temozolomide A dacarbazine derivative that is used as an alkylating antineoplastic agent for the treatment of MALIGNANT GLIOMA and MALIGNANT MELANOMA. 8-Carbamoyl-3-methylimidazo(5,1-d)-1,2,3,5-tetrazin-4(3H)-one,CCRG 81045,CCRG-81045,M&B 39831,M&B-39831,Methazolastone,NSC 362856,NSC-362856,TMZ-Bioshuttle,TMZA-HE,Temodal,Temodar,Temozolomide Hexyl Ester,CCRG81045,M&B39831,NSC362856,TMZ Bioshuttle
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

F Fiorica, and M Berretta, and C Colosimo, and A Stefanelli, and S Ursino, and E Zanet, and T Palmucci, and D Maugeri, and M Malaguarnera, and S Palmucci, and M Grasso, and U Tirelli, and F Cartei
May 2008, Journal of neuro-oncology,
F Fiorica, and M Berretta, and C Colosimo, and A Stefanelli, and S Ursino, and E Zanet, and T Palmucci, and D Maugeri, and M Malaguarnera, and S Palmucci, and M Grasso, and U Tirelli, and F Cartei
December 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology,
F Fiorica, and M Berretta, and C Colosimo, and A Stefanelli, and S Ursino, and E Zanet, and T Palmucci, and D Maugeri, and M Malaguarnera, and S Palmucci, and M Grasso, and U Tirelli, and F Cartei
March 2005, The New England journal of medicine,
F Fiorica, and M Berretta, and C Colosimo, and A Stefanelli, and S Ursino, and E Zanet, and T Palmucci, and D Maugeri, and M Malaguarnera, and S Palmucci, and M Grasso, and U Tirelli, and F Cartei
August 2009, Cancer,
F Fiorica, and M Berretta, and C Colosimo, and A Stefanelli, and S Ursino, and E Zanet, and T Palmucci, and D Maugeri, and M Malaguarnera, and S Palmucci, and M Grasso, and U Tirelli, and F Cartei
October 2013, Clinical neurology and neurosurgery,
F Fiorica, and M Berretta, and C Colosimo, and A Stefanelli, and S Ursino, and E Zanet, and T Palmucci, and D Maugeri, and M Malaguarnera, and S Palmucci, and M Grasso, and U Tirelli, and F Cartei
May 2012, International journal of radiation oncology, biology, physics,
F Fiorica, and M Berretta, and C Colosimo, and A Stefanelli, and S Ursino, and E Zanet, and T Palmucci, and D Maugeri, and M Malaguarnera, and S Palmucci, and M Grasso, and U Tirelli, and F Cartei
April 2013, Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia,
F Fiorica, and M Berretta, and C Colosimo, and A Stefanelli, and S Ursino, and E Zanet, and T Palmucci, and D Maugeri, and M Malaguarnera, and S Palmucci, and M Grasso, and U Tirelli, and F Cartei
January 2014, Neurologia medico-chirurgica,
F Fiorica, and M Berretta, and C Colosimo, and A Stefanelli, and S Ursino, and E Zanet, and T Palmucci, and D Maugeri, and M Malaguarnera, and S Palmucci, and M Grasso, and U Tirelli, and F Cartei
September 2012, Journal of neuro-oncology,
F Fiorica, and M Berretta, and C Colosimo, and A Stefanelli, and S Ursino, and E Zanet, and T Palmucci, and D Maugeri, and M Malaguarnera, and S Palmucci, and M Grasso, and U Tirelli, and F Cartei
January 2009, Journal of neuro-oncology,
Copied contents to your clipboard!